These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32987920)

  • 1. Quasi-Irreversible Inhibition of CYP2D6 by Berberine.
    Kim HG; Lee HS; Jeon JS; Choi YJ; Choi YJ; Yoo SY; Kim EY; Lee K; Park I; Na M; Park HJ; Cho SW; Kim JH; Lee JY; Kim SK
    Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32987920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of Hwang-Ryun-Hae-Dok-Tang on cytochrome P450 in human liver microsomes.
    Lee SY; Jang H; Lee JY; Ma JY; Oh SJ; Kim SK
    Xenobiotica; 2015 Feb; 45(2):131-8. PubMed ID: 25145883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes.
    Li Y; Ren G; Wang YX; Kong WJ; Yang P; Wang YM; Li YH; Yi H; Li ZR; Song DQ; Jiang JD
    J Transl Med; 2011 May; 9():62. PubMed ID: 21569619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
    Desta Z; Wu GM; Morocho AM; Flockhart DA
    Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
    Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
    Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
    Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
    J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
    Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
    J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
    Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK
    Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum.
    Subehan ; Usia T; Kadota S; Tezuka Y
    Planta Med; 2006 May; 72(6):527-32. PubMed ID: 16808005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs.
    Yamamoto T; Hagima N; Nakamura M; Kohno Y; Nagata K; Yamazoe Y
    Xenobiotica; 2004 Jul; 34(7):687-703. PubMed ID: 15672756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes.
    AlRabiah H; Ahad A; Mostafa GAE; Al-Jenoobi FI
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):707-713. PubMed ID: 29744741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
    Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
    Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6.
    Song M; Hong M; Lee MY; Jee JG; Lee YM; Bae JS; Jeong TC; Lee S
    Food Chem Toxicol; 2013 Sep; 59():549-53. PubMed ID: 23835282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
    Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
    Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
    Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
    Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
    Lu P; Schrag ML; Slaughter DE; Raab CE; Shou M; Rodrigues AD
    Drug Metab Dispos; 2003 Nov; 31(11):1352-60. PubMed ID: 14570767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions.
    Micuda S; Mundlova L; Anzenbacherova E; Anzenbacher P; Chladek J; Fuksa L; Martinkova J
    Eur J Clin Pharmacol; 2004 Oct; 60(8):583-9. PubMed ID: 15378224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid method for simultaneous quantification of berberine, berbamine, magnoflorine and berberrubine in mouse serum using UPLC-MS/MS.
    Liang X; Xiang Y; Li Y; Feng P; Qin Y; Lai X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Apr; 1142():122040. PubMed ID: 32145638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells.
    Zhou Y; Cao S; Wang Y; Xu P; Yan J; Bin W; Qiu F; Kang N
    Fitoterapia; 2014 Jan; 92():230-7. PubMed ID: 24321576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
    Ewald AH; Maurer HH
    Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.